4 April 2024 - More than one billion people worldwide live with migraine, and the World Health Organization classifies migraine as the second leading cause of disability in the world.

Nurtec ODT (rimegepant) is now available in Canada for use in the acute treatment of migraine, with or without aura in adults older than 18 years of age. Nurtec is an orally disintegrating calcitonin gene-related peptide receptor antagonist tablet. It was approved by Health Canada on 1 December 2023.

Read Pfizer press release